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Abstract
Objective—To compare perinatal outcomes among women diagnosed with gestational diabetes
by National Diabetes Data Group (NDDG) with women only meeting Carpenter-Coustan criteria.
Study design—Fourteen-year retrospective cohort; women screened positive with 1-hour
glucose load ≥140 mg/dL underwent a diagnostic 3-hour oral glucose tolerance test. We report
adjusted prevalence ratios (aPR) of multivariate analyses.
Results—Of the 4659 screen-positive women with diagnostic testing, 1082 (3.3%, 1082/33,179)
met NDDG criteria; 1542 (4.6%, 1542/33,179), or 460 more, met Carpenter-Coustan. These
untreated 460 women had greater risk of pre-eclampsia than women diagnosed by NDDG criteria
(aPR 1.70, 95% CI 1.23-2.35). They had greater risk of cesarean delivery (aPR 1.16, 95% CI
1.04-1.30) and infants >4000g (aPR 1.25, 95% CI 1.01-1.56) than women not meeting either
diagnostic criteria.
Conclusion—The 42.5% additional women diagnosed only by Carpenter-Coustan criteria are at
greater risk for some adverse outcomes. Cost-effectiveness of a change remains to be determined.
Keywords
gestational diabetes; diagnosis; adverse perinatal outcome; gestational hypertension; pre-
eclampsia
Introduction
Gestational diabetes mellitus (GDM) is diagnosed in 4-7% of pregnancies, and the
prevalence is likely to continue increasing given the epidemic of obesity in the United
States.1, 2 Uncontrolled hyperglycemia in pregnancy is associated with adverse perinatal
outcomes.3, 4 While strict glycemic control of women with GDM improves perinatal
outcomes, screening and diagnostic criteria remain controversial.5
The American Congress of Obstetrics and Gynecology recommends that all pregnant
women be screened for GDM using a random 50g 1-hour glucose load test, followed by a
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diagnostic fasting 100g 3-hour oral glucose tolerance test (OGTT) if their screening test is
positive.6 Two diagnostic criteria for the 3-hour OGTT currently exist. The National
Diabetes Data Group (NDDG) criteria stipulate using fasting, 1-hour, 2-hour, and 3-hour
plasma glucose levels of 105mg/dL, 190mg/dL, 165mg/dL, and 145mg/dL, respectively, for
GDM diagnosis.7 Carpenter-Coustan (CC) criteria are more inclusive with lower threshold
values of 95mg/dL, 180mg/dL, 155mg/dL, and 140mg/dL.8 By both criteria, any two values
at or above established thresholds diagnose GDM. Debate continues regarding the most
appropriate criteria to apply, and both NDDG and CC criteria remain common in the United
States.
Applying Carpenter-Coustan's lower thresholds, as opposed to the NDDG criteria currently
used at UNC Hospitals, would increase the number of women labeled as gestational
diabetics and thus offered treatment. A change to the more inclusive Carpenter-Coustan
criteria may be warranted if these women who are currently undiagnosed and thus untreated
have an increase in adverse perinatal outcomes compared to women with GDM and
treatment by NDDG criteria or those who did not meet either diagnostic criteria. To answer
this question, we assessed perinatal outcomes among all women screened for GDM at our
institution over a 14-year period to evaluate the potential impact of diagnosing GDM by
Carpenter-Coustan compared to the current practice of diagnosing GDM by National
Diabetes Data Group criteria.
Materials and Methods
Study cohort
We performed a retrospective analysis of all women who were eligible for gestational
diabetes (GDM) screening and delivered at UNC Womens’ Hospital, Chapel Hill, NC
between April 1, 1996 and May 31, 2010. We excluded women who delivered prior to 24
weeks’ gestation, those with pre-gestational diabetes mellitus, and those without a
documented GDM screening test result. For multiple gestations, we used neonatal data for
the firstborn. University of North Carolina Institutional Review Board approval was
obtained for this study.
Gestational diabetes diagnosis
GDM screening was performed between 24 and 28 weeks’ gestation using a 50 g, 1-hour
glucose load test, with plasma glucose values ≥ 140 mg/dL considered screen-positive.
Diagnostic testing was offered to these women and performed using a 100 g, 3-hour oral
glucose tolerance test (OGTT). Women meeting National Diabetes Group (NDDG) criteria
were diagnosed with GDM and received nutritional counseling and instruction for glucose
self-monitoring. Women monitored capillary blood glucose with goals set as fasting < 105
mg/dL and 1-hour postprandial < 140 mg/dL or 2-hour postprandial < 130 mg/dL. Adequate
glycemic control at our institution was defined as 50% or more of blood glucose levels at
goal levels. Medical therapy was initiated (subcutaneous insulin or oral glyburide) if
adequate glycemic control was not achieved with diet-control alone as determined by the
primary obstetrical provider.
Women who screened positive (1-hour glucose load ≥140 mg/dL) but did not meet NDDG
diagnostic criteria received routine prenatal care. Three hundred and twenty women who had
1-hour glucose load results that prompted GDM diagnosis by the their primary provider, and
thus did not undergo 3-hour OGTT, were excluded from this analysis.
The three study groups for this analysis included: 1) women who would be diagnosed with
GDM only by CC criteria (CC only); 2) women diagnosed and treated for GDM by NDDG
criteria (NDDG), regardless of subsequent treatment (diet-control vs. medical management
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with insulin or glyburide) required; and 3) women who screened positive but had a negative
3-hour oral glucose tolerance test and were not diagnosed with GDM by either criteria
(negative OGTT).
Data abstraction
Clinical providers prospectively record perinatal data from all deliveries at UNC. Trained
abstractors enter all information into and maintain the UNC Perinatal Database. Prior to
analysis, outliers and clinically implausible values (e.g. maternal age > 50 years or
birthweight > 6000 g) were identified by exploratory analysis and corrected when possible
by review of original paper charts and electronic medical records. A random sample of 200
patient records was cross-referenced with original paper charts and electronic medical
records to assess accuracy of key variables.
We abstracted maternal demographic data and pregnancy diagnoses. Race/ethnicity was
self-reported from choices in the prenatal record (Caucasian, African-American, Hispanic,
or Asian) and was collected to assess the potential relationship between race/ethnicity and
GDM diagnoses and outcomes.
Perinatal Outcomes
We examined perinatal outcomes shown to improve with treatment of mild GDM in
randomized controlled trials or be statistically significant in retrospective studies.5, 9, 10
Measured outcomes included: gestational age at delivery, preterm delivery < 37 weeks,
mode of delivery (spontaneous vaginal delivery, vacuum-assisted vaginal delivery, forceps-
assisted vaginal delivery, or cesarean delivery), 3rd or 4th degree perineal laceration,
gestational hypertension, pre-eclampsia (composite of mild, severe, eclampsia, and/or
HELLP syndrome), birthweight (grams), macrosomia > 4000 g, shoulder dystocia
(abstracted from provider notation in perinatal record), NICU admission, and NICU stay >
48 hours.
Statistical analysis
We compared women who would have only been diagnosed with GDM by the more
inclusive CC criteria (CC only) with each of the other two study groups: women diagnosed
with and treated for GDM by NDDG criteria (NDDG); and women who screened positive
but had a negative OGTT by both diagnostic criteria (negative OGTT). Bivariate analyses
included Students’ t-test and Wilcoxon Rank-sum test for continuous and Pearson's Chi-
square for categorical variables. Means with standard deviations and medians with
interquartile ranges were reported for continuous variables with normal and non-normal
distributions, respectively.
We compared the prevalence of dichotomous adverse outcomes using unadjusted and
adjusted regression models. Significant variables in bivariate analysis and those known to be
strong clinical risk factors for the outcome of interest were considered for inclusion in the
adjusted models. We considered continuous, dichotomous, linear, and squared terms of
potential confounders and report the most parsimonious models. We fit Poisson regression
models with robust standard errors to account for the fact that some women contributed data
on more than one pregnancy during the study period.11 We report adjusted prevalence ratios
(aPR) with 95% confidence intervals (CIs).
We also fit a linear regression model for birthweight as a function of gestational age at
delivery within each group allowing for a non-linear relationship between the two. P-values
< 0.05 and CIs that excluded the null were considered statistically significant. Stata 10 was
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used to perform all analyses (StataCorp, College Station, TX) with the exception of the
linear regression models for which we used SAS 9.1.3 (SAS Institute, Inc, Cary, NC).
Results
Between April 1, 1996 and May 31, 2010, 33,179 women were screened for GDM and thus
met initial study inclusion criteria. A total of 1082 women were diagnosed by NDDG
criteria, and 1542 would be diagnosed by CC criteria. This represents a 42.5% increase in
GDM diagnoses, from 3.3% (1082/33,179) to 4.6% (1542/33,179), using the more inclusive
criteria. On average, an additional 33 women would be diagnosed with GDM per year in our
cohort.
Of the 33,179 women screened, 5454 screened positive for GDM based on a 50g, 1-hour
glucose load ≥140 mg/dL and were neither diagnosed with GDM based solely on this result
nor excluded based on established criteria. Eighty-five percent (4659/5454) underwent a
diagnostic 100 g, 3-hour OGTT and had results available in our database to confirm or
exclude GDM diagnosis (Figure 1). Those who were otherwise eligible but did not have a 3-
hr OGTT result (795/5454, 15%) were more likely to be Caucasian (40% vs. 36%) or
African-American (18% vs. 12%) and less likely to be Hispanic (37% vs. 45%) (p<0.001).
These women had median 1-hour glucose load values of 150 mg/dL [144-162], comparable
to the negative OGTT study group (153 mg/dL [145-163]) and lower than those of the CC
only group (158mg/dL [149-173]) and the NDDG group (169mg/dL [155-188]). As a
sensitivity analysis, we included these 795 women in the negative OGTT group, but the
magnitude and statistical significance of the associations between study group and the
perinatal outcomes did not change.
Of the 4659 women who had a 3-hour OGTT, 23% (1082/4659) were diagnosed with and
treated for GDM by NDDG criteria, comprising the NDDG group. An additional 10%
(460/4659) would have been diagnosed by CC criteria, the CC only group. The 67% who
screened positive (3117/4659) but were not diagnosed by either criteria comprised the
negative OGTT group (Figure 1). Maternal characteristics of the three groups are shown in
Table 1. The CC only group had median 1-hour glucose screening results (158 mg/dL
[149-173]) lower than the NDDG group (169 mg/dL [155-188], p<0.001) and higher than
the negative OGTT group (153 mg/dL [145-163], p<0.001) (Table 1).
As shown in Table 2, in unadjusted analysis, the CC only group was more likely to develop
gestational hypertension and pre-eclampsia than either the NDDG or negative OGTT study
groups. The CC only group was also more likely to deliver by cesarean section and less
likely to have a normal spontaneous vaginal delivery than the negative OGTT group.
Two continuous variables, birthweight and gestational age at delivery, are represented in
Figure 2. At statistically similar gestational ages at delivery, infants born to CC only women
weighed statistically more than infants born to negative OGTT women (3483 g vs. 3387 g,
p<0.05). Compared to infants born to NDDG women, those born to CC only women were
also born at a statistically greater gestational age (39.3 weeks vs. 39.0 weeks, p<0.001) with
a statistically greater birthweight (3483 g vs. 3360 g, p=0.005).
In multivariable regression models, adjusted and unadjusted models did not differ in
statistical significance or overall precision when each potential covariate assessed in
bivariate analysis was considered. Only results of adjusted models are reported, controlling
for parity, maternal delivery age over 35, ethnicity, and delivery year. Models evaluating
cesarean and operative deliveries also controlled for prior cesarean delivery.
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Compared to the NDDG group, women in the CC only group were more likely to have
hypertensive disorders of pregnancy including gestational hypertension (aPR 1.54, 95% CI
1.01 – 2.37) and pre-eclampsia (aPR 1.70, 95% CI 1.23 – 2.35). Compared to the negative
OGTT group, women in the CC only group were at greater risk of both gestational
hypertension (aPR 1.48, 95% CI 1.02 – 2.13) and pre-eclampsia (aPR 1.47, 95% CI 1.02 –
2.13), as they were in comparison to the NDDG group. The CC only group was more likely
to have a cesarean delivery (aPR 1.16, 95% 1.04 – 1.30), and their infants were more likely
to have macrosomia >4000g (aPR 1.25, 95% CI 1.01 – 1.56). (Table 3).
Women in the CC only group were equally likely to have an infant admitted to the NICU as
those in each of the other two groups in unadjusted bivariate analysis. Infants of CC only
women with a NICU admission, however, were less likely to stay in the NICU for over 48
hours than infants of women in the NDDG group (43% vs. 56%, p=0.017) (Table 2). In
adjusted models, there were no significant differences in NICU admission or length of stay >
48 hours among the three groups (Table 3).
Body mass index (BMI) and gestational weight gain have been included in the UNC
Perinatal Database for the past 2 years and were available for 325 women. We conducted a
sensitivity analysis to evaluate the impact of these missing data on this subset of women,
including and excluding BMI from our models. The significant differences or similarities for
each perinatal outcome were not altered by inclusion of BMI.
Comment
Diagnosing gestational diabetes by the more inclusive Carpenter-Coustan (CC) criteria
would identify 42.5% more women for nutritional counseling and treatment during
pregnancy. Women who meet CC criteria but are not treated are at greater risk for
hypertensive disorders of pregnancy and greater infant birthweight, compared to women
diagnosed by NDDG and treated, as well as screen-positive women with a negative OGTT.
These women who meet CC criteria, but not NDDG criteria, represent a group who would
potentially benefit from treatment.
Our study has several strengths. In a comparison of two still commonly used GDM
diagnostic criteria, inclusion of only screen-positive women most closely mimics the at-risk
population who would be impacted if the more inclusive Carpenter-Coustan thresholds were
implemented. Further, we selected adverse perinatal outcomes recently shown to be
associated with GDM.4, 5, 10 We were able to assess the impact of changing diagnostic
criteria on important outcomes such as the hypertensive disorders of pregnancy. Finally, our
statistical modeling strategies may decrease susceptibility to bias in interpretation of results.
Sources of potential bias do exist in this retrospective study design. Selection bias may exist,
as 15% of women who met screening thresholds for a 3-hour OGTT did not undergo the
diagnostic test. In a sensitivity analysis, these women were grouped with the negative OGTT
group with which they were most similar, and results were not affected. Additionally, data
on body mass index (BMI) were only available in the two most recent years of our database.
Again, sensitivity analyses of the subset for which BMI was available indicated that
adjusting for BMI did not meaningfully alter the estimates in that subgroup. While we
cannot determine the impact of BMI prior to data availability, this suggests that BMI, like
most other potential covariates, did not alter overall relationships between perinatal
outcomes between study group comparisons. Finally, differing risk of cesarean delivery
among the groups must be interpreted with caution. We do not know the primary indication
for cesarean delivery, and a diagnosis of GDM may influence counseling for and decision to
perform a cesarean delivery.
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We cannot determine causal associations of differences or similarities in outcomes between
the NDDG and CC only study groups in this retrospective study. As prevalence ratios did
not generally exceed 1.5, even with significant confidence intervals, these overall weak
associations may be due to chance. Despite this, clinically relevant differences may still
exist. On the contrary, some statistically significant differences may not be clinically
relevant. For example, although the NDDG and CC only groups differed statistically in
gestational age and birthweight, both were born at 39 or more weeks and differed by only
123 g. Despite the study's strengths, these limitations are important as a change to more
inclusive diagnostic criteria would change clinical practice and increase costs to an already
over-burdened health care system.
Our results expand on prior work on the association between GDM diagnostic criteria and
pregnancy outcome. The higher disease prevalence among CC women is comparable to four
large nationally representative populations, each reporting on a change from NDDG to
Carpenter-Coustan diagnostic criteria.9, 12-14 In general, the similarity we observed in the
NDDG and CC only study groups in the rates of specific perinatal outcomes were also
consistent with the published findings from other studies. But compared to other studies, our
study is significant because we found much more modest (not statistically significant)
increases in the risk of macrosomia9 and shoulder dystocia9, 12, 15 in the CC only study
group compared to the NDDG group, which differs from what has been previously reported
and emphasizes the complexity of selecting diagnostic criteria. Nonetheless, prospective
data by Landon, et al. have shown women with some degree of hyperglycemia or mild GDM
benefit from treatment, with lower prevalence of some perinatal morbidities.10
It is important to note that despite recent data, the more inclusive Carpenter-Coustan criteria
is not universally implemented. These retrospective studies, including ours, report data on
current clinical practice, and National Diabetes Data Group criteria remain common.
Furthermore, the 5th International Workshop on Gestational Diabetes Mellitus did not make
specific recommendations regarding which diagnostic criteria should be used.16 Given the
lack of one consistent recommendation, and ongoing debate in the obstetric community, it is
critical to objectively evaluate how a change in current clinical practice will impact patients
and our ability to care for them.
Interpreting our findings with those previously published suggest implementation of more
inclusive GDM diagnostic criteria may be warranted. Providing additional women with the
associated nutritional counseling and self-glucose monitoring may improve glycemic control
and thus decrease adverse perinatal outcomes.17 Gestational diabetes is a known risk factor
for future Type II diabetes mellitus and related long-term poor health outcomes and may be
associated with an increased risk of childhood obesity.18-20 Future work should consider
long-term benefits of diagnosis and treatment, balanced with the potential for harm, as
diagnosis may also lower women's perception of their children's and their own health
status.21
With an economic burden of GDM estimated at $636 million per year in the U.S., based on
a 4.5% disease incidence22, a shift to more inclusive criteria will have an immediate impact
on disease prevalance and associated costs. Our data suggest the additional 33 women who
would be diagnosed with GDM per year at our institution may benefit from treatment,
though this cannot be concluded from a retrospective analysis. Changing clinical practice
has inherent challenges and must be individual decisions based on patient population and
available resources. Cost-effectiveness studies will help quantify the risks and benefits of
increasing GDM prevalence by 42.5% at our institution and at the population level as the
obstetric community continues to debate diagnostic thresholds to guide our management of
GDM and optimize short- and long-term perinatal outcomes.
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Women diagnosed with gestational diabetes by Carpenter-Coustan but not by National
Diabetes Data Group Criteria, have greater risk of adverse perinatal outcomes when left
untreated.
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Flow diagram of inclusion and exclusion criteria for three study groups (CC only, NDDG,
and negative OGTT) of women eligible for gestational diabetes (GDM) screening
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Inset of weeks 38 to 40 to show relationship between gestational age at delivery and
birthweight for the three study groups with symbols placed at the median gestational age at
delivery.
BERGGREN et al. Page 11

























BERGGREN et al. Page 12
Table 1
Maternal characteristics by study group: Carpenter-Coustan (CC only) vs. National Diabetes Data Group
(NDDG) and Carpenter-Coustan (CC only) vs. negative oral glucose tolerance test (negative OGTT)
Mean (SD), Median [IQR], or No. (%)
*
CC only (n = 460) vs. NDDG (n = 1082) vs. negative OGTT (n = 3117)
Maternal age at delivery (years) 30.6 (6.0) 30.7 (5.8)
29.4 (5.8)
§
Maternal age at delivery
    At or over 35 years 113 (25) 253 (23)
559 (18)
§
    Under 35 years 347 (75) 829 (77) 2558 (82)
Ethnicity
    Caucasian 156 (34) 309 (29) 1215 (39)
    African-American 58 (13) 154 (14) 360 (12)
    Latina 207 (45) 551 (51) 1338 (43)
    Asian 29 (6) 47 (4) 162 (5)






Multiparity 304 (66) 704 (65)
1898 (61)
§
Chronic hypertension 39 (8) 95 (9)
138 (4)
§
Multiple gestation 8 (2) 32 (3) 102 (3)
History of pre-eclampsia 12 (2)
64 (6)
‡ 117 (4)
History of gestational diabetes 7 (2)
39 (4)
‡ 44 (1)
Previa diagnosis 5 (1) 19 (2) 53 (2)
Induction of labor 149 (32) 403 (37)
772 (25)
§
Prior cesarean 77 (17) 208 (19) 537 (17)
Breech presentation 11 (2) 30 (3) 65 (2)
Placental abruption 4 (1) 12 (1) 45 (1)
Preterm premature rupture of membranes 39 (8) 91 (8) 254 (8)
*
numbers (%); percents may not total 100 due to rounding; SD is standard deviation; [IQR] is inter-quartile range
†
median reported for one-hour glucose load (mg/dL)
‡
significant between CC (n=460) vs. NDDG (n=1082) groups
§
significant between CC (n=460) vs. negative OGTT (n=3117) groups
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Table 2
Bivariate analysis of perinatal outcomes: Carpenter-Coustan (CC only) vs. National Diabetes Data Group
(NDDG) and Carpenter-Coustan (CC only) vs. negative oral glucose tolerance test (negative OGTT)
Median [IQR] or No. (%)
*
CC only (n = 460) vs. NDDG (n = 1082) vs. negative OGTT (n = 3117)




Preterm delivery under 37 weeks 66 (14) 178 (16) 403 (13)
Mode of delivery
    Normal spontaneous vaginal delivery 270 (59) 608 (56)
1923 (62)
§
    Vacuum-assisted vaginal delivery 11 (2) 28 (3) 141 (5)
    Forceps-assisted vaginal delivery 19 (4) 38 (4) 111 (4)
    Cesarean delivery 160 (35) 407 (38) 942 (30)
3rd/4th degree laceration 14 (3) 41 (4) 118 (4)
















Macrosomia > 4000 g 78 (17) 146 (14)
411 (13)
§
Low birthweight < 2500 g 37 (8) 117 (11) 316 (10)
Shoulder dystocia 24 (5) 40 (4) 109 (4)
NICU admission 138 (30) 350 (32) 804 (26)
Among infants admitted to NICU (n=1262), length of stay:
    < 48 hours 78 (57) 152 (44) 375 (48)




numbers (%); percents may not total 100 due to rounding; [IQR] is inter-quartile range
†
median reported for gestational age at delivery and birthweight (grams); total ns account for missing precise gestational age at delivery for 35
individuals; CC only (n=455), NDDG (n=1072), negative OGTT (n=3097)
‡
significant for CC (n=460) vs NDDG (n=1082)
§
significant for CC (n=460) vs negative OGTT (n=3117)
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Table 3
Adjusted prevalence ratios (aPR) comparing women diagnosed with GDM by: Carpenter-Coustan (CC only)
vs. National Diabetes Data Group (NDDG) and Carpenter-Coustan (CC only) vs. negative oral glucose
tolerance test (negative OGTT)
CC only (n=460) vs. NDDG (n=1082) criteria CC only (n=460) vs. negative OGTT (n=3117)
Perinatal outcome aPR (95% CI)
* aPR (95% CI)
Preterm delivery under 37 weeks 0.85 (0.66 – 1.10) 1.09 (0.86 – 1.39)
Cesarean delivery 0.96 (0.85 – 1.05) 1.16 (1.04 – 1.30)
Operative vaginal delivery 1.14 (0.76 – 1.70) 0.97 (0.68 – 1.39)
3rd or 4th degree perineal laceration 0.79 (0.44 – 1.45) 0.83 (0.48 – 1.44)
Gestational hypertension 1.54 (1.01 – 2.37) 1.48 (1.02 – 2.13)
Pre-eclampsia 1.70 (1.23 – 2.35) 1.47 (1.02 – 2.13)
Macrosomia > 4000g 1.26 (0.98 – 1.56) 1.25 (1.01 – 1.56)
Low birthweight < 2500 g 0.73 (0.51 – 1.03) 0.79 (0.57 – 1.10)
Shoulder dystocia 1.43 (0.87 – 2.32) 1.41 (0.91 – 2.18)
NICU admission (any) 0.93 (0.79 – 1.09) 1.15 (0.99 – 1.33)
NICU stay over 48 hours 0.73 (0.56 – 0.95) 0.97 (0.76 – 1.25)
*
adjusted prevalence ratio (aPR), 95% confidence interval (CI); all models controlled for parity, maternal delivery age over 35, ethnicity, delivery
year; cesarean and operative deliveries also controlled for prior cesarean
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